Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patients.
Recruiting
- Conditions
- Phosphoproteomics - phosphoproteomicsResponse prediction - therapieselectierenal cell cancer - nierkankerkinase inhibitors - kinaseremmers
- Registration Number
- NL-OMON26770
- Lead Sponsor
- VU Medical Center
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 225
Inclusion Criteria
1. Patients with advanced (unresectable and/or metastatic) renal cell cancer;
2. Patients who will start treatment with sunitinib, pazopanib, sorafenib, axitinib or everolimus;
Exclusion Criteria
1. Clinical findings associated with an unacceptably high tumor biopsy risk, according to the judgement of the investigator;
2. Radiotherapy on target lesions during study or within 4 weeks of the start of study drug;
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The phosphoproteomics profile of the tumor biopsy before treatment will be determined and correlated with radiological response and progression-free survival.
- Secondary Outcome Measures
Name Time Method 1. The relationship between the PamChip kinase activity profile for the initiation of therapy and progression-free survival;<br /><br>2. The relationship between the genetic mutation profile of the primary tumor based on MPS and progression-free survival;<br /><br>3. The relationship between the serum peptide profile before and during treatment and progression-free survival;<br /><br>4. The relationship between the number and type of immune regulatory cells in blood and tissue and progression-free survival;<br /><br>5. The relationship between genetic polymorphisms and pharmacokinetic parameters and progression-free survival;<br /><br>6. The relationship between protein profile tumorexosomen from urine and serum and progression-free survival.